Status:
COMPLETED
Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Lead Sponsor:
University of California, San Diego
Conditions:
Hereditary Hemorrhagic Telangiectasia (HHT)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Terence M. Davidson, MD is conducting a research study to find out more about the topical application of Avastin (proper chemical name is bevacizumab) in the treatment of epistaxis (nose bleeding) in ...
Detailed Description
Plans are to recruit patients with HHT from the UCSD Nasal Dysfunction Clinic. The HHT world is connected through the HHT Foundation. The Foundation is interested in VEGF inhibitors. They have careful...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adults over the age of 18
- Both male and non-pregnant females adults capable of making informed consent who have HHT by Curacao criteria and whose nasal bleeding due to HHT is of such a magnitude that it requires medical care
- Additionally, females of childbearing age will be given a pregnancy test as a preliminary measure to ensure that those who become involved are not at risk.
Exclusion
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2014
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01397695
Start Date
June 1 2009
End Date
January 1 2014
Last Update
September 6 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Diego Medical Center
San Diego, California, United States, 92103